Meta-analyses suggest that aspirin use is associated with modest increases in ICH incidence305 but the absolute ICH risk in unselected populations appears to be small relative to the absolute numbers of MIs and ischemic A small observational study found that antiplatelet use was common after ICH and did not appear to be associated with an increase in the risk of ICH recurrence in 127 survivors of lobar hemorrhage (HR, 0.8; 95% CI, 0.3 2.3; P=0.73) and 80 survivors of deep hemorrhage (HR, 1.2; 95% There are conflicting reports regarding the use of statins in patients with ICH.308 312 In the Stroke Prevention With Aggressive Reduction in Cholesterol Levels (SPARCL) study, the benefit of high-dose atorvastatin in reducing recurrent ischemic stroke was offset in part by an increased risk of ICH. Secondary analysis found that statin treatment, increasing age, and having ICH as the qualifying stroke for study enrollment were factors associated with later ICH However, a meta-analysis of 31 randomized controlled trials that included 91 588 statin-treated patients found no significant association between statin use and ICH all-cause mortality were significantly reduced with statin A Markov analysis evaluating the risks and ben- efits of statin therapy in patients with prior ICH concluded that if statin use does increase the risk of ICH, avoidance of statins should be considered in patients with ICH, particu- larly those with lobar ICH.311 Concordant with these con- clusions, statin use and age were independently associated with the presence and number of microbleeds, especially in cortical locations, in ICH patients.313 In contrast, continued statin use after ICH was associated with early neurologi- cal improvement and reduced 6-month mortality in a small There are no data on whether the reported propensity for ICH with statin use is dose depen- dent. 